Kitty Yale Email

EVP and Chief Development Officer . Akero Therapeutics

South San Francisco, CA

Location

k****@akerotx.com

Primary Email

Current Roles

Employees:
72
Revenue:
$5.4M
About
Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Akero Therapeutics Address
601 Gateway Boulevard
South San Francisco, CA
United States
Akero Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.